[Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].

CONCLUSION: In selected patients, neoadjuvant therapy with ICI is well tolerated and can induce a complete remission of the tumor. Treatment with ICI has no negative impact on the surgical procedure. Prognosis seems to be promising in CPR and limited in PPR. PMID: 32820489 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32820489?dopt=Abstract

Source: Pneumologie - August 22, 2020 Category: Respiratory Medicine Tags: Pneumologie Source Type: research